Louisiana State Employees Retirement System Buys Shares of 10,100 Zimmer Biomet Holdings, Inc. $ZBH

Louisiana State Employees Retirement System bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,100 shares of the medical equipment provider’s stock, valued at approximately $913,000.

Several other institutional investors also recently modified their holdings of ZBH. DV Equities LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $25,000. Monetary Solutions Ltd bought a new position in Zimmer Biomet in the fourth quarter valued at approximately $30,000. Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet during the 4th quarter worth $31,000. Flagship Harbor Advisors LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth $32,000. Finally, Grove Bank & Trust raised its position in shares of Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 328 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH opened at $87.50 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company has a fifty day simple moving average of $86.09 and a 200 day simple moving average of $89.79. The stock has a market cap of $16.93 billion, a P/E ratio of 22.73, a P/E/G ratio of 2.58 and a beta of 0.46.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm’s revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Analysts Set New Price Targets

ZBH has been the topic of a number of analyst reports. Truist Financial reissued a “hold” rating and issued a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Robert W. Baird set a $92.00 price objective on Zimmer Biomet in a report on Wednesday, April 29th. Wells Fargo & Company cut their target price on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Barclays decreased their target price on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. Finally, Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $102.70.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.